New pill targets common cancer driver in major trial
NCT ID NCT06973564
Summary
This study is testing a new oral drug called JAB-23E73 for adults with advanced solid tumors that have a specific genetic change called a KRAS alteration. The main goals are to find a safe and effective dose and to see if the drug can shrink tumors. It is for people whose cancer has progressed and is not suitable for curative surgery or radiation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cleveland Clinic Foundation
RECRUITINGCleveland, Ohio, 44195, United States
-
Huntsman Cancer Institute
RECRUITINGSalt Lake City, Utah, 84112, United States
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
-
Washington University
RECRUITINGSt Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.